ArticleNature communications2021
Small RNA mediated gradual control of lipopolysaccharide biosynthesis affects antibiotic resistance in Helicobacter pylori.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Correlation versus causation:mSphere · 2026Article
- Progress in immunotherapy forFrontiers in cellular and infection microbiology · 2026Review
- A 5'-UTR cis-acting RNA element targeted by RNase III is essential for DNA simple sequence repeat-dependent phase variation in Haemophilus influenzae.Nucleic acids research · 2025Article
- ThemBio · 2025Article
- Identification of Released Bacterial Extracellular Vesicles Containing Lpp20 fromMicroorganisms · 2025Article
- Large diversity in the O-chain biosynthetic cluster within populations of Pelagibacterales.mBio · 2025Article
- RNase Y mediates posttranscriptional control of the virulence-associated CncR1 small-RNA iniScience · 2025Article
- Advances in Helicobacter pylori lipopolysaccharide structure and function.FEMS microbiology reviews · 2025Review
- High salt condition alters LPS synthesis and induces the emergence of drug resistance mutations inAntimicrobial agents and chemotherapy · 2024Article
- Regulation of bacterial gene expression by non-coding RNA: It is all about time!Cell chemical biology · 2024Review
- Roles of Lipopolysaccharide Glycosyltransferases in Maintenance ofInternational journal of molecular sciences · 2023Article
- Antimicrobial resistance and mechanisms of epigenetic regulation.Frontiers in cellular and infection microbiology · 2023Review
- Helicobacter pylori shows tropism to gastric differentiated pit cells dependent on urea chemotaxis.Nature communications · 2022Article
- Review
- The role of non-coding RNA in the diagnosis and treatment ofFrontiers in medicine · 2022Review
- Riboregulation in the Major Gastric PathogenFrontiers in microbiology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The small, regulatory RNA RepG (Regulator of polymeric G-repeats) regulates the expression of the chemotaxis receptor TlpB in Helicobacter pylori by targeting a variable G-repeat in the tlpB mRNA leader. Here, we show that RepG additionally controls lipopolysaccharide (LPS) phase variation by also modulating the expression of a gene (hp0102) that is co-transcribed with tlpB. The hp0102 gene encodes a glycosyltransferase required for LPS O-chain biosynthesis and in vivo colonization of the mouse stomach. The G-repeat length defines a gradual (rather than ON/OFF) control of LPS biosynthesis by RepG, and leads to gradual resistance to a membrane-targeting antibiotic. Thus, RepG-mediated modulation of LPS structure might impact host immune recognition and antibiotic sensitivity, thereby helping H. pylori to adapt and persist in the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.